Clinical-stage Oncology Company Beats Q4 Earnings & Revenue Estimates
Cardiff Oncology Beats Q4 Earnings and Revenue Estimates: What it Means for Investors.
Cardiff Oncology (NASDAQ: $CRDF), a clinical-stage biotechnology company, has just reported its fourth quarter results. The company beat analyst consensus estimates on both earnings and revenue, marking a significant milestone in its financial performance. $Cardiff Oncology(CRDF.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Papanice : But it can't fly